PRTA NASDAQ
Prothena Corporation plc
1W: -0.9%
1M: +1.3%
3M: -1.9%
YTD: -8.7%
1Y: -13.8%
3Y: -81.2%
5Y: -86.7%
$8.81
+0.41 (+4.88%)
After Hours: $8.75 (-0.06, -0.68%)
Weekly Expected Move ±6.8%
$7
$8
$8
$9
$9
Credit Risk of going bust: lower than 83% of companies Debt: 1.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Prothena Corporation plc would be worth roughly what it owes.
Total debt $7.0M against a stock market value of $431.2M.
Distance to default 10.45 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.0M (short-term plus half of long-term), stock volatility 47.4%; Altman Z'' 9.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $7.0M against a stock market value of $431.2M.
Distance to default 10.45 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $3.0M (short-term plus half of long-term), stock volatility 47.4%; Altman Z'' 9.96. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-08-03
Earliest Filing
2024-05-28
Latest Filing
partner: 4
licensee: 1
Counterparties (Filed by PRTA)
5 relationshipsCompanies named in PRTA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Bristol Myers Squibb | CELG-RI | partner | Entered into a Global License Agreement for PRX019 and exercised IND Option under Master Collaboration Agreement | 2024-05-28 | View |
| Bristol Myers Squibb | CELG-RI | partner | Entered into a Global License Agreement granting BMS exclusive global rights to develop, manufacture, and commercialize | 2023-07-10 | View |
| Arcus Biosciences, Inc. | RCUS | partner | Sublandlord in a sublease agreement for office and laboratory space. | 2022-10-31 | View |
| HCP LS Brisbane, LLC | — | partner | Master Landlord providing consent to the sublease agreement. | 2022-10-31 | View |
| Bristol Myers Squibb | CELG-RI | licensee | BMS exercised an option to enter into an exclusive U.S. license for PRX005 and other antibody programs under the Master | 2021-08-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Officer/Director Change | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-05-15 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-02-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-12 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-11-19 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-27 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-06-18 | Costs Associated with Exit or Disposal Activities; Departure/Election of Directors; Appointment of O | View | |
| 2025-06-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-23 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-16 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-30 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR